FilingReader Intelligence

CSPC Pharmaceutical gets China approval for dupilumab biosimilar trials

August 19, 2025 at 09:40 AM UTCBy FilingReader AI

CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to commence clinical trials for its Dupilumab Injection, a biosimilar to Dupixent.

The recombinant fully human monoclonal antibody targets IL-4R α and is indicated for treating moderate-to-severe atopic dermatitis in adults. Non-clinical studies showed high similarity to the reference drug in quality, safety, and efficacy.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when CSPC Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →